Good MorningA much-needed market correction is underway and may not end soon. The sell-off was sparked by a sell-the-news event that has yet to play out. The news was the June CPI report, which was affirmed by the PCE price index; consumer inflation is falling closer to the FOMC's target of 2%, paving the path toward an interest rate cut. The significant detail is the interest rate cut, a move that will signal the easing of economic headwinds and a pivot for the market. That pivot will be into small and mid-cap names, driven by the expectation improving business conditions will drive growth and profits.
This week's risk is the FOMC. The FOMC is meeting on Tuesday and Wednesday and will release a fresh policy statement on Wednesday. The market is pricing in a rate cut for August and a high probability for a second in September. Still, the FOMC may hesitate to commit, inducing volatility in the market. The takeaway is that underlying economic conditions and outlook remain bullish; a stock market correction should result in a buy-the-dip opportunity and fresh all-time highs later this year. Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Technology | | The earnings reports from Alphabet Inc. (NASDAQ: GOOGL) and Tesla Inc. (NASDAQ: TSLA) led technology stocks lower for the week. Some analysts are warning that the price action is due to an artificial intelligence (AI) bubble, but there could be other factors at play.
First, the second half of Jul... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Finance | | The world of cryptocurrency is still a developing thesis, with some raging bulls on every coin out there and others calling the asset class a complete scam and Ponzi scheme. Whether one side is right or wrong is up for debate, but one thing remains true: investor and trader psychology and behavior.
... Read the Full Story |
|
Technology | | Owning stock gives investors a one-for-one behavior in the underlying stock, and that’s good enough when there is a longer timeframe. But it won’t cut it for big traders looking to quickly get a hit-and-run stock move.
That’s where stock options come in. They allow investors to ac... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Multi-Sector Conglomerates | |
3M’s (NYSE: MMM) rebound is gaining momentum because of surprisingly good results. Today’s story is that repositioning efforts are taking hold and driving improved profitability while litigation risks dwindle. The takeaways from the Q2 report include better-than-expected top and bottom... Read the Full Story |
|
Finance | |
Some names in the retail and apparel sectors have made a splash in investors’ monitors in recent weeks, even months. Unfortunately, the attention is founded on seriously bearish price action, like the fact that shares of Lululemon Athletica Inc. (NASDAQ: LULU) are now trading at only 48% of ... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Technology | |
As earnings season unfolds and several mega-cap tech stocks, including members of the "Magnificent Seven," have reported, the overall market and tech sector have seen significant declines in recent weeks. The XLK technology sector ETF has dropped nearly 6% this month and is now down over 10% from ... Read the Full Story |
|
Technology | |
ServiceNow Inc. (NYSE: NOW), a leading provider of cloud-based software solutions, has recently made headlines with a notable 15% surge in its stock price following a strong earnings report.
This impressive gain brings its year-to-date performance to nearly 20%, and the stock has just broken o... Read the Full Story |
|
Medical | |
Molina Healthcare, Inc. (NYSE: MOH) is a leading provider of managed healthcare services, primarily focusing on government-sponsored programs such as Medicaid and Medicare. Molina Healthcare’s earnings report for the second quarter was released, and it sent shockwaves through the market, p... Read the Full Story |
|
Markets | |
AstraZeneca PLC (NASDAQ: AZN) is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%. The total return of the SPDR S&P ... Read the Full Story |
|
Medical | |
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and ... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. | Should I Buy Edwards Lifesciences Stock? EW Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Wednesday, July 15, 2026 at 6:41 PM.
Edwards Lifesciences Bull Case -
The company reported earnings per share of $0.78 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
-
Quarterly revenue reached approximately $1.65 billion, reflecting a year-over-year increase of about 16.7%, showcasing the company's ability to expand its market presence.
-
Edwards Lifesciences Co. has a solid net margin of 17.39%, suggesting efficient management of expenses relative to revenue, which can lead to higher profitability.
-
Institutional investors hold a significant portion of the company's stock, with ownership at around 79.46%, indicating confidence from large financial entities in the company's future prospects.
-
The current stock price is around $96.39, which is within a favorable range according to analysts' target prices, suggesting potential for appreciation.
Edwards Lifesciences Bear Case -
Despite strong earnings, the stock has received mixed ratings from analysts, with some maintaining a "hold" rating, which may indicate uncertainty about future performance.
-
Recent price targets from analysts vary significantly, with some as low as $85.00, suggesting potential volatility and differing opinions on the stock's value.
-
The company operates in a highly competitive medical technology sector, which can pose risks to market share and profitability as new innovations emerge.
-
While revenue growth is promising, any slowdown in the healthcare market or changes in regulations could adversely affect the company's performance.
-
Investors should consider the overall economic environment, as fluctuations in the market can impact stock performance, especially in the healthcare sector.
| | View Today's Stock Pick |
|
